Briumvi Now Available for Multiple Sclerosis Treatment
The CD20-directed cytolytic antibody therapy was approved based on data from two phase 3 trials.
The CD20-directed cytolytic antibody therapy was approved based on data from two phase 3 trials.
The approval was based on data from the phase 3 ULTIMATE 1 and ULTIMATE 2 trials that compared ublituximab-xiiy to teriflunomide in patients with relapsing multiple sclerosis.
Slowing of disability progression and higher likelihood of disability improvement observed compared with standard disease-modifying therapies
More pediatric patients free of new or newly enlarging T2 lesions at week 96 with dimethyl fumarate versus interferon beta-1a
About 48 percent of participants receiving ublituximab had infusion-related reactions
Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis.
The application is under review for relapsing forms of multiple sclerosis and Crohn disease.
Stay up-to-date on the latest drugs in development.
Most neurological disorders do not appear to be more frequent after COVID-19 than after influenza or bacterial pneumonia